Evidence map›Paper›PMID 36831433›Full record

ArticleCancers2023

Combining Breast Cancer Risk Prediction Models.

Zoe Guan, Theodore Huang, Anne Marie McCarthy, Kevin Hughes, Alan Semine, Hajime Uno, Lorenzo Trippa, Giovanni Parmigiani, Danielle Braun

Abstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zoe GuanDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10017, USA.ORCID 0000-0002-1015-4666
Theodore HuangVertex Pharmaceuticals, Boston, MA 02210, USA.
Anne Marie McCarthyDepartment of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA.
Kevin HughesDepartment of Surgery, Medical University of South Carolina, Charleston, SC 29425, USA.
Alan SemineAdvanced Image Enhancement, Fall River, MA 02720, USA.
Hajime UnoDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0003-0622-8471
Lorenzo TrippaDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Giovanni ParmigianiDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA 02115, USA.ORCID 0000-0002-8783-5961
Danielle BraunDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI JENNIFER W MACK · 1985 to 2026
$330.6M
Training Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3M
Training Grant in Quantitative Sciences for Cancer ResearchT32CA009337 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI QUACKENBUSH, JOHN, TRIPPA, LORENZO · 1986 to 2025
$12.3M
Statistical Methods and Validation Analyses for the Integration of External Data in Clinical TrialsR01LM013352 · NLM · DANA-FARBER CANCER INST · PI TRIPPA, LORENZO · 2021 to 2024
$1.5M
NCI NIH HHS 5P30CA006516-56NCI NIH HHS 5T32CA009337-40NCI NIH HHS N01 PC074400NCI NIH HHS N01PC74400-6-0-1NCI NIH HHS P30 CA006516NCI NIH HHS P30 CA008748NCI NIH HHS T32 CA 009001NCI NIH HHS T32 CA009001NCI NIH HHS T32 CA009337NLM NIH HHS R01 LM013352
6 · The paper itself

Abstract

Accurate risk stratification is key to reducing cancer morbidity through targeted screening and preventative interventions. Multiple breast cancer risk prediction models are used in clinical practice, and often provide a range of different predictions for the same patient. Integrating information from different models may improve the accuracy of predictions, which would be valuable for both clinicians and patients. BRCAPRO is a widely used model that predicts breast cancer risk based on detailed family history information. A major limitation of this model is that it does not consider non-genetic risk factors. To address this limitation, we expand BRCAPRO by combining it with another popular existing model, BCRAT (i.e., Gail), which uses a largely complementary set of risk factors, most of them non-genetic. We consider two approaches for combining BRCAPRO and BCRAT: (1) modifying the penetrance (age-specific probability of developing cancer given genotype) functions in BRCAPRO using relative hazard estimates from BCRAT, and (2) training an ensemble model that takes BRCAPRO and BCRAT predictions as input. Using both simulated data and data from Newton-Wellesley Hospital and the Cancer Genetics Network, we show that the combination models are able to achieve performance gains over both BRCAPRO and BCRAT. In the Cancer Genetics Network cohort, we show that the proposed BRCAPRO + BCRAT penetrance modification model performs comparably to IBIS, an existing model that combines detailed family history with non-genetic risk factors.

Indexed as

BCRATBRCAPROensemble learningmodel aggregationstacking

Identifiers

PMID36831433
PMCPMC9953824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.